A pragmatic randomised controlled trial comparing the effectiveness and cost effectiveness of levetiracetam and zonisamide versus standard treatments for epilepsy: a comparison of Standard And New Antiepileptic Drugs (SANAD-II).
Project Summary: The objectives of SANAD-II are to: (i) compare the longer term clinical effectiveness and cost effectiveness of initiating monotherapy with: (a) lamotrigine, levetiracetam or zonisamide for patients with untreated focal onset seizures; (b) valproate or levetiracetam for patients with untreated generalized onset seizures or seizures that are difficult to classify; (ii) compare QOL outcomes of initiating standard or new AEDs; and examine the development and evolution of QOL impairments in patients with newly treated epilepsy; (iii) establish a DNA bank linked to a database containing clinical outcome data and epilepsy phenotype